Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2014

01.05.2014 | short review

Current therapeutic concepts in mucosa-associated lymphoid tissue (MALT) lymphoma

verfasst von: MD Barbara Kiesewetter, MD Markus Raderer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

While eradication of Helicobacter pylori leads to durable remissions in up to 75 % of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma and therefore, has been well established as first-line therapy of choice, there is no standard of care for relapsed, refractory or extragastric MALT lymphoma. Both in gastric as well as extragastric MALT lymphoma, local therapy results in high rates of local control, but MALT lymphoma may be disseminated in a significant number of patients, making systemic treatment approaches reasonable. Different classical cytostatic agents have successfully been tested in the past. However, MALT lymphoma usually runs an indolent clinical course and thus, recent trials have focussed on chemotherapeutics with a favourable toxicity profile, e.g. chlorambucil or bendamustine with or without rituximab (R), and new immunomodulatory drugs, e.g. lenalidomide. Results are promising and further, and especially more mature data with a longer follow-up are awaited. In addition, efforts have been made to characterise the activity of antibiotic therapy in extragastric MALT lymphoma, particularly in the setting of ocular adnexal manifestations. Doxycyclin-treatment achieved response rates of 45–65 % in several series, which was independent of the presence of a Chlamydophila psittaci infection. Furthermore, the macrolide antibiotic clarithromycin has become a matter of interest for the treatment of ocular adnexal MALT lymphoma as this substance exerts not only antibiotic, but also direct anti-tumor and immunomodulatory effects. In view of recent data, this short review focuses on highlights and recent results of systemic and antimicrobial therapy in MALT lymphoma.
Literatur
1.
Zurück zum Zitat Jaffe ES, Harris NL, Stein H, et al. Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC; 2008, pp. 158–66. Jaffe ES, Harris NL, Stein H, et al. Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC; 2008, pp. 158–66.
2.
Zurück zum Zitat Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;52(8):1410–6. PubMedCrossRef Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;52(8):1410–6. PubMedCrossRef
3.
Zurück zum Zitat Isaacson PG, Chott A, Nakumura S, et al. Extranodal marginal cell lymphoma of mucosa-associated tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC;2008, pp. 214–9. Isaacson PG, Chott A, Nakumura S, et al. Extranodal marginal cell lymphoma of mucosa-associated tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC;2008, pp. 214–9.
4.
Zurück zum Zitat Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8):3034–44. PubMedCrossRef Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8):3034–44. PubMedCrossRef
5.
Zurück zum Zitat Zucca E, Copie-Bergmann C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi144–8. doi:10.1093/annonc/mdt343. Zucca E, Copie-Bergmann C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi144–8. doi:10.1093/annonc/mdt343.
6.
Zurück zum Zitat Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60(6):747–58. doi:10.1136/gut.2010.224949. PubMedCrossRef Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60(6):747–58. doi:10.1136/gut.2010.224949. PubMedCrossRef
7.
Zurück zum Zitat Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21(22):4157–64. PubMedCrossRef Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21(22):4157–64. PubMedCrossRef
8.
Zurück zum Zitat Son SH, Choi BO, Kim GW, et al. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma). Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):86–91. doi:10.1016/j.ijrobp.2009.04.018. PubMedCrossRef Son SH, Choi BO, Kim GW, et al. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma). Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):86–91. doi:10.1016/j.ijrobp.2009.04.018. PubMedCrossRef
9.
Zurück zum Zitat Vaillant JC, Ruskoné-Fourmestraux A, Aegerter P, et al. Management and long-term results of surgery for localized gastric lymphomas. Am J Surg. 2000;179(3):216–22. PubMedCrossRef Vaillant JC, Ruskoné-Fourmestraux A, Aegerter P, et al. Management and long-term results of surgery for localized gastric lymphomas. Am J Surg. 2000;179(3):216–22. PubMedCrossRef
10.
Zurück zum Zitat Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95(3):802–6. PubMed Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95(3):802–6. PubMed
11.
Zurück zum Zitat Raderer M, Streubel B, Woehrer S, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res. 2005;11(9):3349–52. PubMedCrossRef Raderer M, Streubel B, Woehrer S, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res. 2005;11(9):3349–52. PubMedCrossRef
12.
Zurück zum Zitat Avilés A, Nambo MJ, Neri N, et al. Mucosa associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled trial. Med Oncol. 2005;22(1):57–62. PubMedCrossRef Avilés A, Nambo MJ, Neri N, et al. Mucosa associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled trial. Med Oncol. 2005;22(1):57–62. PubMedCrossRef
13.
Zurück zum Zitat Raderer M, Wohrer S, Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology. 2006;70(6):411–7. PubMedCrossRef Raderer M, Wohrer S, Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology. 2006;70(6):411–7. PubMedCrossRef
14.
Zurück zum Zitat Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue. Cancer. 2009;115(22):5210–7. doi:10.1002/cncr.24605. PubMedCrossRef Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue. Cancer. 2009;115(22):5210–7. doi:10.1002/cncr.24605. PubMedCrossRef
15.
Zurück zum Zitat Jäger G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002;20(18): 3872–7. PubMedCrossRef Jäger G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002;20(18): 3872–7. PubMedCrossRef
16.
Zurück zum Zitat Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995;13(10):2524–9. PubMed Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995;13(10):2524–9. PubMed
17.
Zurück zum Zitat Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis if the IELSG-19 Randomized Study. J Clin Oncol. 2013;31(5):565–72. doi: 10.1200/JCO.2011.40.6272. PubMedCrossRef Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis if the IELSG-19 Randomized Study. J Clin Oncol. 2013;31(5):565–72. doi: 10.1200/JCO.2011.40.6272. PubMedCrossRef
18.
Zurück zum Zitat Lévy M, Copie-Berman C, Amiot A, et al. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leuk Lymphoma. 2013;54(5):940–4. doi:10.3109/10428194.2012.729832. PubMedCrossRef Lévy M, Copie-Berman C, Amiot A, et al. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leuk Lymphoma. 2013;54(5):940–4. doi:10.3109/10428194.2012.729832. PubMedCrossRef
19.
Zurück zum Zitat Aguiar-Bujanda D, Llorca-Martinez I, Rivero-Vera JC, et al. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone. Hematol Oncol. 2013. doi:10.1002/hon.2105. Aguiar-Bujanda D, Llorca-Martinez I, Rivero-Vera JC, et al. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone. Hematol Oncol. 2013. doi:10.1002/hon.2105.
20.
Zurück zum Zitat Salar A, Domingo-Domenech E, Panizo C, et al. Final results of a multicenter phase II trial with bendamustine and rituximab as first line treatment for patients with MALT lymphoma (MALT-2008-01). ASH 2012 Annual Meeting (abstr 3691). Salar A, Domingo-Domenech E, Panizo C, et al. Final results of a multicenter phase II trial with bendamustine and rituximab as first line treatment for patients with MALT lymphoma (MALT-2008-01). ASH 2012 Annual Meeting (abstr 3691).
21.
Zurück zum Zitat Kiesewetter B, Mayerhoefer ME, Lukas J, et al. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Ann Hematol 2013. Epub ahead of print. Kiesewetter B, Mayerhoefer ME, Lukas J, et al. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Ann Hematol 2013. Epub ahead of print.
22.
Zurück zum Zitat Troch M, Kiesewetter B, Willenbacher W, et al. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013;98(2):264–8. doi:10.3324/haematol.2012.072587. PubMedCentralPubMedCrossRef Troch M, Kiesewetter B, Willenbacher W, et al. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013;98(2):264–8. doi:10.3324/haematol.2012.072587. PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Kiesewetter B, Troch M, Dolak W, et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Haematologica. 2013;98(3):353–6. doi:10.3324/haematol.2012.065995. PubMedCentralPubMedCrossRef Kiesewetter B, Troch M, Dolak W, et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Haematologica. 2013;98(3):353–6. doi:10.3324/haematol.2012.065995. PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Kiesewetter B, Raderer M. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood. 2013;122(8):1350–7. doi:10.1182/blood-2013-02-486522. PubMedCrossRef Kiesewetter B, Raderer M. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood. 2013;122(8):1350–7. doi:10.1182/blood-2013-02-486522. PubMedCrossRef
25.
Zurück zum Zitat Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;96(8):586–94. Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;96(8):586–94.
26.
Zurück zum Zitat Chanudet E, Zhou Y, Bacon CM, et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol. 2006;209(3):344–51. PubMedCrossRef Chanudet E, Zhou Y, Bacon CM, et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol. 2006;209(3):344–51. PubMedCrossRef
27.
Zurück zum Zitat Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012;30(24):2988–94. doi:10.1200/JCO.2011.41.4466. PubMedCrossRef Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012;30(24):2988–94. doi:10.1200/JCO.2011.41.4466. PubMedCrossRef
28.
Zurück zum Zitat Kim TM, Kim KH, Lee MJ, et al. First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of clinical predictors. Cancer Sci. 2010;101(5):1199–203. doi:10.1111/j.1349-7006.2010.01502.x. PubMedCrossRef Kim TM, Kim KH, Lee MJ, et al. First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of clinical predictors. Cancer Sci. 2010;101(5):1199–203. doi:10.1111/j.1349-7006.2010.01502.x. PubMedCrossRef
29.
Zurück zum Zitat Ferreri AJ, Ponzoni M, Guidoboni M, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006;98(19):1375–82. PubMedCrossRef Ferreri AJ, Ponzoni M, Guidoboni M, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006;98(19):1375–82. PubMedCrossRef
30.
Zurück zum Zitat Govi S, Dognini GP, Licata G, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol. 2010;150(2):226–9. doi:10.1111/j.1365-2141.2010.08179.x. PubMed Govi S, Dognini GP, Licata G, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol. 2010;150(2):226–9. doi:10.1111/j.1365-2141.2010.08179.x. PubMed
31.
Zurück zum Zitat Aoki D, Ueno S, Kubo F, et al. Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by supression VEGF production. Anticancer Res 2005;25(1A):133–8. PubMed Aoki D, Ueno S, Kubo F, et al. Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by supression VEGF production. Anticancer Res 2005;25(1A):133–8. PubMed
Metadaten
Titel
Current therapeutic concepts in mucosa-associated lymphoid tissue (MALT) lymphoma
verfasst von
MD Barbara Kiesewetter
MD Markus Raderer
Publikationsdatum
01.05.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0131-2